Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.60 |
| ▸ | CTSK | P43235 | 5/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753714 | 1.00 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL3997764 | 1.00 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL17015 | 1.00 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4893696 | 0.90 | CTSS (0.50) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4663069 | 0.90 | CTSS (0.57) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4922934 | 0.87 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL7029037 | 0.87 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4922943 | 0.87 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL755370 | 0.87 | CTSS (0.45) | CTSSCTSK | |
| SCHEMBL18526772 | 0.87 | CTSS (0.45) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486762-A | Novel compound and use method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-02 | — | — | CN | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| CN-101001841-A | Tetrahydroquinolones and aza-analogues thereof useful as DPP-IV inhibitors for the treatment of diabetes | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | CN | disclosed |
| EP-1791536-A1 | 1-[(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL]-PYRROLIDINE-(2R)-CARBOXYLIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| EP-1786806-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| EP-1758861-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121131-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005120494-A1 | 1-`(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL !-PYRROLIDINE-(2R)-CARBOXILIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005040095-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1406622-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1406622-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | Merck & Co., Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003000181-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | CTSS 505/4885CTSK 426/4885ATM 4787/4885 |
| US-20080015146-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP3 | CTSS 550/4885CTSK 361/4885ATM 4682/4885 |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | CTSS 2636/4885CTSK 3323/4885ATM 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.